BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21045197)

  • 1. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
    Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
    Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
    Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
    Hsu FJ; Caspar CB; Czerwinski D; Kwak LW; Liles TM; Syrengelas A; Taidi-Laskowski B; Levy R
    Blood; 1997 May; 89(9):3129-35. PubMed ID: 9129015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I; Qin H; Kwak LW
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
    Davis TA; Maloney DG; Czerwinski DK; Liles TM; Levy R
    Blood; 1998 Aug; 92(4):1184-90. PubMed ID: 9694706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.
    Warncke M; Buchner M; Thaller G; Dodero A; Bulashevska A; Pfeifer D; Timmer J; Veelken H
    Cancer Immunol Immunother; 2011 Jan; 60(1):49-60. PubMed ID: 20848095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
    J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW; Campbell MJ; Czerwinski DK; Hart S; Miller RA; Levy R
    N Engl J Med; 1992 Oct; 327(17):1209-15. PubMed ID: 1406793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine therapy for B-cell lymphomas: next-generation strategies.
    Neelapu SS; Kwak LW
    Hematology Am Soc Hematol Educ Program; 2007; ():243-9. PubMed ID: 18024636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.